Trials / Completed
CompletedNCT00264004
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD2171 | 30 mg \& 45 mg oral tablet |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-01-01
- Completion
- 2011-04-01
- First posted
- 2005-12-12
- Last updated
- 2012-08-29
- Results posted
- 2012-08-29
Locations
6 sites across 3 countries: Germany, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00264004. Inclusion in this directory is not an endorsement.